


 Cite this: *RSC Adv.*, 2025, 15, 947

Retraction: Yiqi Fumai lyophilized injection attenuates doxorubicin-induced cardiotoxicity, hepatotoxicity and nephrotoxicity in rats by inhibition of oxidative stress, inflammation and apoptosis

 Yue Gu,^a Aichun Ju,^b Bingjie Jiang,^a Jingze Zhang,^{*c} Shuli Man,^{*d} Changxiao Liu^{†e} and Wenyuan Gao^{*a}

 DOI: 10.1039/d5ra90003d
[rsc.li/rsc-advances](https://doi.org/10.1039/d5ra90003d)

 Retraction of 'Yiqi Fumai lyophilized injection attenuates doxorubicin-induced cardiotoxicity, hepatotoxicity and nephrotoxicity in rats by inhibition of oxidative stress, inflammation and apoptosis' by Yue Gu *et al.*, *RSC Adv.*, 2018, 8, 40894–40911, <https://doi.org/10.1039/C8RA07163B>.

The Royal Society of Chemistry, with the agreement of the authors below, hereby wholly retracts this *RSC Advances* article due to concerns with the reliability of the data.

There are several duplications of image panels within this paper with images published in other papers by different authors; Fig. 7C YQFM/TGF- β 1 panel with ref. 1, Fig 11C YQFM/Liver with ref. 2, Fig 11B Control/Liver with ref. 3, Fig 11C DOX/Liver with ref. 3, Fig 11B YQFM/Heart with ref. 4 and Fig 11F western blot GADPH band with ref. 5.

Within the paper, there are many duplications including the Fig. 10A DOX/Kidney (COX-2) panel with the Fig. 11D DOX/Kidney (Cytochrome C) panel, the Fig. 11A DOX + YQFM/Heart (BAX) panel with the Fig. 11B DOX + YQFM/Heart (BCI-2) panel, and the BCI-2 western blot bands within Fig. 11F and G.

The authors state that they obtained the images in Fig. 7C, 8A–L, 10A, 11A–G and 12A–L from a third party.

Given the significance of these concerns, the Editor has lost confidence that the findings presented in this paper are reliable.

Signed: Yue Gu, Bingjie Jiang, Shuli Man, Aichun Ju, Jingze Zhang, Wenyuan Gao

Date: 17th December 2024

Retraction endorsed by Laura Fisher, Executive Editor, *RSC Advances*

References

- 1 Y. Li, T. Xia, R. Li, G. Tse, T. Liu and G. Li, *Med. Sci. Monit.*, 2019, 25, 1582–1589.
- 2 X.-B. Zheng, X.-B. Chen, L.-L. Xu, M. Zhang, L. Feng, P.-S. Yi, J.-W. Tang and M.-Q. Xu, *Cancer Sci.*, 2017, 108, 338–346.
- 3 J.-J. Liu, Y. Xu, S. Chen, C.-F. Hao, J. Liang and Z.-L. Li, *World J. Gastroenterol.*, 2022, 28, 4635–4648.
- 4 N. Cheng, C. Jin, P. Jin, D. Zhu and Z. Hou, *J. Cell. Mol. Med.*, 2021, 25, 6137, DOI: [10.1111/jcmm.16527](https://doi.org/10.1111/jcmm.16527).
- 5 Z. Zhuang, D. Yu, Z. Chen, D. Liu, G. Yuan, N. Yirong, L. Sun, Y. Liu, R. He and K. Wang, *J. Evidence-Based Complementary Altern. Med.*, 2019, 2019, 1–12.

^aTianjin Key Laboratory for Modern Drug Delivery and High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Weijin Road, Tianjin 300072, China. E-mail: pharmgao@tju.edu.cn; Fax: +86-22-87401895; Tel: +86-22-87401895

^bTasly Pride Pharmaceutical Company Limited, Tianjin 300410, China

^cDepartment of Pharmacy, Logistics University of Chinese People's Armed Police Forces, Tianjin 300309, China. E-mail: zhangjingze1877@163.com; Tel: +86-22-84876773

^dState Key Laboratory of Food Nutrition and Safety, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, China. E-mail: mssl@tust.edu.cn; Tel: +86-22-60601265

^eThe State Key Laboratories of Pharmacodynamics and Pharmacokinetics, Tianjin 300193, China

† Deceased.

